

Udaya S Tantry

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6483438/udaya-s-tantry-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

239
papers

13,428
citations

54
h-index

112
g-index

302
ext. papers

15,282
ext. citations

5.7
avg, IF

6.21
L-index

#	Paper	IF	Citations
239	Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 302, 849-57	27.4	1070
238	Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 919-33	15.1	913
237	Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. <i>Circulation</i> , 2009 , 120, 2577-85	16.7	866
236	Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 2261-73	15.1	693
235	Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1820-6	15.1	561
234	Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1827-32	15.1	461
233	Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. <i>Circulation</i> , 2010 , 121, 1188-99	16.7	372
232	Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 657-66	15.1	328
231	The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 1392-6	15.1	317
230	Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. <i>Circulation</i> , 2005 , 111, 1153-9	16.7	312
229	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. <i>Annals of Internal Medicine</i> , 2015 , 163, 40-51	8	281
228	Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1705-9	15.1	258
227	Nitric oxide regulates wound healing. <i>Journal of Surgical Research</i> , 1996 , 63, 237-40	2.5	225
226	Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. <i>European Heart Journal</i> , 2015 , 36, 1762-71	9.5	218
225	International Expert Consensus on Switching Platelet P2Y Receptor-Inhibiting Therapies. <i>Circulation</i> , 2017 , 136, 1955-1975	16.7	215
224	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 1566-1579	27.4	205
223	Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET CABG) study. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 261-9	6	196

222	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 1521-1537	5	189
221	The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 531-3	15.1	187
220	Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 1785-94	27.4	176
219	The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. <i>Diabetes</i> , 2007 , 56, 3014-9	0.9	174
218	Clopidogrel resistance?. <i>Thrombosis Research</i> , 2007 , 120, 311-21	8.2	137
217	First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. <i>Circulation: Cardiovascular Genetics</i> , 2010 , 3, 556-66		135
216	Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 185-93	15.1	132
215	Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. <i>American Heart Journal</i> , 2010 , 160, 346-54	4.9	123
214	The difference between clopidogrel responsiveness and posttreatment platelet reactivity. <i>Thrombosis Research</i> , 2005 , 115, 89-94	8.2	123
213	Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. <i>Annals of Internal Medicine</i> , 2013 , 158, 261-70	8	115
212	The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 505-12	15.1	104
211	First report of the point-of-care TEG: A technical validation study of the TEG-6S system. <i>Platelets</i> , 2016 , 27, 642-649	3.6	101
210	Combination antithrombotic therapies. <i>Circulation</i> , 2010 , 121, 569-83	16.7	96
209	Nitric oxide in the healing wound: a time-course study. <i>Journal of Surgical Research</i> , 2001 , 101, 104-8	2.5	95
208	Nitric oxide metabolism in wounds. <i>Journal of Surgical Research</i> , 1997 , 71, 25-31	2.5	94
207	Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. <i>Circulation: Cardiovascular Interventions</i> , 2011 , 4, 585-94	6	91
206	Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. <i>Platelets</i> , 2008 , 19, 595-604	3.6	89
205	Drug insight: Clopidogrel nonresponsiveness. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006 , 3, 387-95		89

204	Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. <i>Circulation</i> , 2012 , 125, 1276-87; discussion 1287	16.7	85
203	Intra-abdominal sepsis impairs colonic reparative collagen synthesis. <i>American Journal of Surgery</i> , 1996 , 171, 102-7; discussion 107-8	2.7	84
202	Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. <i>Circulation: Cardiovascular Genetics</i> , 2013 , 6, 184-92		80
201	Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 189-97	9.4	71
200	Genotyping: one piece of the puzzle to personalize antiplatelet therapy. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 112-6	15.1	71
199	Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 2186-91	15.1	71
198	Platelet activation in myocardial ischemic syndromes. <i>Expert Review of Cardiovascular Therapy</i> , 2004 , 2, 535-45	2.5	69
197	The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. <i>American Heart Journal</i> , 2011 , 161, 598-604	4.9	68
196	Aspirin resistance. <i>Progress in Cardiovascular Diseases</i> , 2009 , 52, 141-52	8.5	64
195	The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. <i>American Heart Journal</i> , 2011 , 162, 160-5	4.9	63
194	The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. <i>Journal of Cardiovascular Pharmacology</i> , 2011 , 57, 86-93	3.1	62
193	Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic Risk Progression (TRIP) study. <i>Platelets</i> , 2010 , 21, 360-7	3.6	62
192	Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009 , 5, 989-1004	5.5	62
191	Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. <i>American Heart Journal</i> , 2012 , 164, 35-42	4.9	60
190	Bleeding and thrombosis associated with ventricular assist device therapy. <i>Journal of Heart and Lung Transplantation</i> , 2017 , 36, 1164-1173	5.8	57
189	Dark chocolate effect on platelet activity, C-reactive protein and lipid profile: a pilot study. <i>Southern Medical Journal</i> , 2008 , 101, 1203-8	0.6	56
188	Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats. <i>Wound Repair and Regeneration</i> , 2000 , 8, 547-53	3.6	56
187	Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 648-57	15.1	55

186	Resistance to antiplatelet drugs: current status and future research. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 2027-45	4	54
185	G-protein-coupled receptors signaling pathways in new antiplatelet drug development. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 500-12	9.4	53
184	Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. <i>Circulation</i> , 2019 , 139, 2170-2185	16.7	49
183	AZD6140. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 225-9	5.9	48
182	Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. <i>Thrombosis Research</i> , 2007 , 121, 107-15	8.2	47
181	The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 422-432	7	47
180	Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. <i>American Journal of Cardiology</i> , 2009 , 104, 525-30	3	46
179	Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 43, 437-445	5.1	44
178	Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 397-409	6.2	44
177	Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. <i>JACC: Cardiovascular Interventions</i> , 2011 , 4, 365-80	5	43
176	Aspirin and clopidogrel resistance: consideration and management. <i>Journal of Interventional Cardiology</i> , 2006 , 19, 439-48	1.8	43
175	Clopidogrel efficacy and cigarette smoking status. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 2495-6	27.4	42
174	Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. <i>Platelets</i> , 2007 , 18, 414-23	3.6	42
173	Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. <i>American Journal of Cardiology</i> , 2009 , 103, 1546-50	3	41
172	Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review. <i>Annals of Internal Medicine</i> , 2016 , 164, 600-7	8	40
171	Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. <i>JACC: Heart Failure</i> , 2014 , 2, 1-14	7.9	40
170	Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. <i>Thrombosis Research</i> , 2007 , 119, 563-70	8.2	40
169	Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates. <i>Nature Biomedical Engineering</i> , 2020 , 4, 1188-1196	19	40

168	Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. <i>Blood Coagulation and Fibrinolysis</i> , 2008 , 19, 268-75	1	38
167	Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. <i>American Heart Journal</i> , 2014 , 168, 530-6	4.9	36
166	The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting. <i>Platelets</i> , 2009 , 20, 97-104	3.6	36
165	Platelet-Mediated Thrombosis: From Bench to Bedside. <i>Circulation Research</i> , 2016 , 118, 1380-91	15.7	36
164	Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. <i>American Heart Journal</i> , 2008 , 155, 56-61	4.9	35
163	Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. <i>European Heart Journal</i> , 2012 , 33, 2151-62	9.5	32
162	Stimulation of fibroblast proliferation and matrix contraction by wound fluid. <i>International Journal of Biochemistry and Cell Biology</i> , 1997 , 29, 231-9	5.6	32
161	Direct oral anticoagulants: a review on the current role and scope of reversal agents. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 49, 271-286	5.1	30
160	Sepsis impairs anastomotic collagen gene expression and synthesis: a possible role for nitric oxide. <i>Journal of Surgical Research</i> , 1997 , 69, 81-6	2.5	29
159	Inflammatory changes during the common cold are associated with platelet activation and increased reactivity of platelets to agonists. <i>Blood Coagulation and Fibrinolysis</i> , 2007 , 18, 713-8	1	29
158	Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy?. <i>Annals of Thoracic Surgery</i> , 2016 , 102, 2010-2017	2.7	28
157	Resistance to antiplatelet drugs: what progress has been made?. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 2553-64	4	28
156	Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to "aspirin resistance". <i>American Heart Journal</i> , 2010 , 159, 744-8	4.9	28
155	Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity. <i>American Journal of Cardiology</i> , 2015 , 115, 716-23	3	27
154	Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation. <i>Thrombosis Research</i> , 2012 , 129, 1-2	8.2	26
153	Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 265-71	7	26
152	Cangrelor: an emerging therapeutic option for patients with coronary artery disease. <i>Current Medical Research and Opinion</i> , 2014 , 30, 813-28	2.5	24
151	The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 589-97	7	23

150	Peri-operative platelet function testing: the potential for reducing ischaemic and bleeding risks. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 248-52	7	23
149	Is There a Role for Preoperative Platelet Function Testing in Patients Undergoing Cardiac Surgery During Antiplatelet Therapy?. <i>Circulation</i> , 2018 , 138, 2145-2159	16.7	23
148	Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery. <i>Annals of Thoracic Surgery</i> , 2010 , 90, 1040-51	2.7	22
147	Ticagrelor for the treatment of arterial thrombosis. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 2251-9	4	21
146	Current antiplatelet treatment strategy in patients with diabetes mellitus. <i>Diabetes and Metabolism Journal</i> , 2015 , 39, 95-113	5	20
145	Should Antithrombotic Treatment Strategies in East Asians Differ from Caucasians?. <i>Current Vascular Pharmacology</i> , 2018 , 16, 459-476	3.3	20
144	Assessment of oral antithrombotic therapy by platelet function testing. <i>Nature Reviews Cardiology</i> , 2011 , 8, 572-9	14.8	18
143	Clopidogrel resistance: implications for coronary stenting. <i>Current Pharmaceutical Design</i> , 2006 , 12, 1261-9	3.9	18
142	Prasugrel. <i>Expert Opinion on Investigational Drugs</i> , 2006 , 15, 1627-33	5.9	18
141	Personalizing Antithrombotic Therapy in COVID-19: Role of Thromboelastography and Thromboelastometry. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1594-1596	7	18
140	Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications. <i>Current Heart Failure Reports</i> , 2016 , 13, 319-328	2.8	17
139	The platelet-related effects of tenecteplase versus alteplase versus reteplase. <i>Blood Coagulation and Fibrinolysis</i> , 2005 , 16, 1-7	1	17
138	2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. <i>Science Bulletin</i> , 2019 , 64, 166-179	10.6	17
137	Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 713-24	7	16
136	Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 447-62	2.5	16
135	Platelet reactivity and thrombogenicity in postmenopausal women. <i>Menopause</i> , 2013 , 20, 57-63	2.5	16
134	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium.. <i>Nature Reviews Cardiology</i> , 2022 ,	14.8	16
133	Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. <i>Current Pharmaceutical Design</i> , 2013 , 19, 3795-815	3.3	15

132	Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy. <i>American Journal of Cardiology</i> , 2015 , 115, 1204-11	3	14
131	Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. <i>Journal of the American Heart Association</i> , 2014 , 3, e001167	6	14
130	Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1851-1865	4	14
129	Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 653-665	4	13
128	Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading. <i>American Heart Journal</i> , 2013 , 166, 95-103	4.9	13
127	Vorapaxar: a novel protease-activated receptor-1 inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 1445-53	5.9	13
126	P2Y12 receptor inhibitors for secondary prevention of ischemic stroke. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 1149-65	4	12
125	Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography: A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis. <i>Journal of Interventional Cardiology</i> , 2016 , 29, 168-78	1.8	12
124	Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity. <i>Platelets</i> , 2013 , 24, 166-9	3.6	12
123	Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2016 , 118, 1941-1947	3	12
122	Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCElERated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study.	3.2	11
121	Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2009 , 11, 22-32	2.1	11
120	GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes. <i>Lancet, The</i> , 2017 , 389, 1773-1775	40	10
119	"Blueprinting" thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 192-199	5.1	10
118	Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 911-922	7	10
117	Drug delivery and therapeutic impact of extended-release acetylsalicylic acid. <i>Future Cardiology</i> , 2016 , 12, 45-58	1.3	10
116	Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - A meta-analysis. <i>International Journal of Cardiology</i> , 2018 , 269, 292-297	3.2	10
115	Unravelling the smokersParadox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y inhibitors. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 1187-90	7	10

114	Platelet Reactivity and Coagulation Markers in Patients with COVID-19. <i>Advances in Therapy</i> , 2021 , 38, 3911-3923	4.1	10
113	A narrative review of the cardiovascular risks associated with concomitant aspirin and NSAID use. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 16-30	5.1	10
112	Vorapaxar in the secondary prevention of atherothrombosis. <i>Expert Review of Cardiovascular Therapy</i> , 2015 , 13, 1293-305	2.5	9
111	Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations. <i>EclinicalMedicine</i> , 2020 , 29, 100647	11.3	9
110	Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 45, 469-476	5.1	9
109	Oxidized Low-Density Lipoprotein-β-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2016 , 118, 673-8	3	9
108	Thienopyridine efficacy and cigarette smoking status. <i>American Heart Journal</i> , 2013 , 165, 693-703	4.9	9
107	Low-density lipoprotein 4: a novel predictor of coronary artery disease severity. <i>Current Medical Research and Opinion</i> , 2017 , 33, 1979-1984	2.5	9
106	Importance of potent P2Y ₁₂ receptor blockade in acute myocardial infarction: focus on prasugrel. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1771-96	4	9
105	Modulation of growth factor and cytokine expression by nitric oxide during rat colon anastomotic healing. <i>Journal of Gastrointestinal Surgery</i> , 2003 , 7, 393-9	3.3	9
104	Differential cytokine expression in skin graft healing in inducible nitric oxide synthase knockout mice. <i>Plastic and Reconstructive Surgery</i> , 2001 , 108, 1251-9	2.7	9
103	A novel method of studying wound healing. <i>Journal of Surgical Research</i> , 2001 , 98, 16-20	2.5	9
102	Response variability and the role of platelet function testing. <i>Journal of Invasive Cardiology</i> , 2009 , 21, 172-8	0.7	9
101	Gender differences in thrombogenicity among patients with angina and non-obstructive coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 373-381	5.1	8
100	Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases. <i>Drug, Healthcare and Patient Safety</i> , 2010 , 2, 233-40	1.6	8
99	Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention. <i>Diabetes Care</i> , 2012 , 35, 2194-7	14.6	8
98	Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. <i>Cardiology Journal</i> , 2012 , 19, 230-42	1.4	8
97	Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 902-904	5.1	8

96	Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel: The Role of VerifyNow. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 724-5	3.8	8
95	Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono- and dual-antiplatelet therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 23-35	15.4	8
94	Selection of P2Y Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome. <i>Progress in Cardiovascular Diseases</i> , 2018 , 60, 460-470	8.5	7
93	Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 323-31	7	7
92	Peri-Procedural Platelet Reactivity in Percutaneous Coronary Intervention. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 1131-1140	7	6
91	Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. <i>American Heart Journal</i> , 2013 , 165, 176-82	4.9	6
90	Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. The result of the ACCEL-DIP Study. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 1198-208	7	6
89	Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 12-20	7	6
88	Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes. <i>Circulation: Cardiovascular Interventions</i> , 2011 , 4, 118-20	6	6
87	Wound fluid inhibits wound fibroblast nitric oxide synthesis. <i>Journal of Surgical Research</i> , 2004 , 122, 43-8.5	8.5	6
86	Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 454-465	5.1	6
85	Pharmacodynamic Profile and Prevalence of Bleeding Episode in East Asian Patients with Acute Coronary Syndromes Treated with Prasugrel Standard-Dose versus De-escalation Strategy: A Randomized A-MATCH Trial. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1376-1386	7	6
84	Antithrombotic Strategies and Device Thrombosis. <i>Cardiology Clinics</i> , 2018 , 36, 541-550	2.5	6
83	Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 123-131	4	5
82	Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 449-456	7	5
81	Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 1259-67	2.5	5
80	Platelet Function Testing in Patients on Antiplatelet Therapy before Cardiac Surgery. <i>Anesthesiology</i> , 2020 , 133, 1263-1276	4.3	5
79	Investigational drugs in phase II clinical trials for acute coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 33-47	5.9	5

78	Meta-Analysis of the Usefulness of Therapeutic Hypothermia After Cardiac Arrest. <i>American Journal of Cardiology</i> , 2020 , 133, 48-53	3	5
77	First Experience Addressing the Prognostic Utility of Novel Urinary Biomarkers in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab274	1	5
76	State of the art: Oral antiplatelet therapy. <i>JRSM Cardiovascular Disease</i> , 2016 , 5, 2048004016652514	1.1	5
75	Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. <i>Journal of Diabetes and Its Complications</i> , 2016 , 30, 1365-70	3.2	5
74	Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences. <i>Korean Circulation Journal</i> , 2021 , 51, 202-221	2.2	5
73	Vorapaxar in the treatment of cardiovascular diseases. <i>Future Cardiology</i> , 2020 , 16, 373-384	1.3	4
72	The Impact of platelet-fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 50, 969-981	5.1	4
71	Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , 2018 , 16, 419-429	2.5	4
70	Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 1029-49	2.5	4
69	Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 1547-56	2.5	4
68	Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin. <i>Expert Review of Clinical Pharmacology</i> , 2014 , 7, 645-53	3.8	4
67	Immunity to thrombotic events is achievable if we stop the guessing game: is this the major hidden message from GRAVITAS?. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 263-4	7	4
66	Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. <i>Thrombosis Research</i> , 2010 , 126, 384-5	8.2	4
65	Smoking and cardiovascular diseases: paradox greater than expected?. <i>Polish Archives of Internal Medicine</i> , 2019 , 129, 700-706	1.9	4
64	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. <i>Cardiology Journal</i> , 2020 , 27, 661-676	1.4	4
63	First In-Human Experience With Inhaled Acetylsalicylic Acid for Immediate Platelet Inhibition: Comparison With Chewed and Swallowed Acetylsalicylic Acid. <i>Circulation</i> , 2020 , 142, 1305-1307	16.7	4
62	Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B and agonist-induced platelet aggregation. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 260-264	5.1	4
61	Thrombogenicity markers for early diagnosis and prognosis in COVID-19: a change from the current paradigm?. <i>Blood Coagulation and Fibrinolysis</i> , 2021 , 32, 544-549	1	4

60	Platelet activation and pneumonia: is soluble p-selectin the right marker?. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1492-3	15.1	3
59	Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case-control study. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 50, 484-498	5.1	3
58	Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events. <i>Expert Review of Cardiovascular Therapy</i> , 2016 , 14, 1361-1370	2.5	3
57	Association of weight gain with coronary artery disease, inflammation and thrombogenicity. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 41, 394-403	5.1	3
56	Cangrelor for the treatment of patients with Arterial Thrombosis. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1389-1398	4	3
55	Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2013 , 168, 427-35	3.2	3
54	Central aortic pulse pressure, thrombogenicity and cardiovascular risk. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 44, 223-233	5.1	3
53	Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration: the ACCEL-PARAZOL study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014 , 21, 1121-39	4	3
52	Does Gender have an Influence on Platelet Function and the Efficacy of Oral Antiplatelet Therapy?. <i>Interventional Cardiology Clinics</i> , 2012 , 1, 223-230	1.4	3
51	PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection. <i>Future Cardiology</i> , 2013 , 9, 785-97	1.3	3
50	Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes.. <i>Journal of Thrombosis and Thrombolysis</i> , 2022 , 53, 363	5.1	3
49	International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 992-998	5.1	3
48	Thrombogenicity and central pulse pressure to enhance prediction of ischemic event occurrence in patients with established coronary artery disease: The MAGMA-ischemia score. <i>Atherosclerosis</i> , 2018 , 268, 55-62	3.1	3
47	Thromboxane inhibition during concurrent therapy with low-dose aspirin and over-the-counter naproxen sodium. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 45, 18-26	5.1	3
46	Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials. <i>Progress in Cardiovascular Diseases</i> , 2020 , 63, 243-248	8.5	2
45	Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. <i>Expert Review of Cardiovascular Therapy</i> , 2016 , 14, 779-91	2.5	2
44	Role of Inflammation and Hypercoagulability in Thrombosis 2014 , 45-50		2
43	Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading: the results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study. <i>International Journal of Cardiology</i> , 2014 , 174, 129-32	3.2	2

42	Platelet Activation and Aggregation in Patients with Advanced Adenocarcinoma Undergoing Chemotherapy: Correlation with a Validated Venous Thromboembolism Risk Score. <i>Blood</i> , 2015 , 126, 3445-3445	2.2	2
41	HDL-C is a Marker of Coronary Artery Disease Severity and Inflammation in Patients on Statin Therapy. <i>Cardiovascular Revascularization Medicine</i> , 2019 , 20, 1001-1006	1.6	2
40	Influence of Amlodipine on Haemostatic Measurements during Clopidogrel Treatment in Patients with Coronary Artery Disease. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 264-273	7	2
39	Clinical applications of antiplatelet therapy. <i>Reviews in Cardiovascular Medicine</i> , 2006 , 7, 130-46; quiz 148-9	3.9	2
38	Antiplatelet therapy beyond 2012: role of personalized medicine 2012 , 122, 298-305		2
37	Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy?. <i>Platelets</i> , 2015 , 26, 608-9	3.6	1
36	Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. <i>Future Cardiology</i> , 2020 , 16, 69-75	1.3	1
35	Secondary prevention of ischaemic stroke: more evidence to block two pathways affecting platelet activation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019 , 5, 275-278	4.6	1
34	Clopidogrel Resistance 2014 , 285-292		1
33	Update: Acute coronary syndromes (V). Personalized antiplatelet therapy. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014 , 67, 480-7	0.7	1
32	PRASFIT-ACS: important evidence against a "one-guideline-fits-all-races" approach to antiplatelet therapy. <i>Circulation Journal</i> , 2014 , 78, 2563	2.9	1
31	The Role of Platelet Function Testing in Risk Stratification and Clinical Decision-Making. <i>Interventional Cardiology Clinics</i> , 2013 , 2, 607-614	1.4	1
30	Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. <i>Platelets</i> , 2017 , 28, 187-193	3.6	1
29	Letter by Grbel et al regarding article, "administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome". <i>Circulation: Cardiovascular Interventions</i> , 2014 , 7, 273	6	1
28	Antiplatelet resistance--fact or myth?. <i>The American Heart Hospital Journal</i> , 2009 , 7, 50-7		1
27	Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. <i>Cardiology Journal</i> , 2021 ,	1.4	1
26	Effects of Monotherapy with Clopidogrel vs. Aspirin on Vascular Function and Hemostatic Measurements in Patients with Coronary Artery Disease: The Prospective, Crossover I-LOVE-MONO Trial. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
25	An Ex Vivo Study to Evaluate the Effect of Tegaserod on Platelet Activation and Aggregation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021 , 26, 40-50	2.6	1

24	The role of viscoelastic testing in assessing peri-interventional platelet function and coagulation. <i>Platelets</i> , 2021 , 1-11	3.6	1
23	Current options in oral antiplatelet strategies during percutaneous coronary interventions. <i>Reviews in Cardiovascular Medicine</i> , 2011 , 12 Suppl 1, S4-13	3.9	1
22	Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography.. <i>TH Open</i> , 2021 , 5, e570-e576	2.7	0
21	Association Between Thrombogenicity Indices and Coronary Microvascular Dysfunction in Patients With Acute Myocardial Infarction. <i>JACC Basic To Translational Science</i> , 2021 , 6, 749-761	8.7	0
20	Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent.. <i>Journal of Experimental Pharmacology</i> , 2021 , 13, 957-970	3	0
19	Antithrombotic treatment strategies after PCI. <i>Lancet, The</i> , 2020 , 395, 866-867	4.0	
18	Assessing platelet reactivity after drug eluting stent implantation: state of the art. <i>Expert Review of Cardiovascular Therapy</i> , 2020 , 18, 17-24	2.5	
17	Light Transmission Aggregometry 2014 , 51-57		
16	Thrombelastography and Other Novel Techniques 2014 , 102-107		
15	Platelet Pathophysiology and its Role in Thrombosis 2014 , 1-7		
14	Personalizing Antiplatelet Therapy 2014 , 267-276		
13	Ticagrelor in the treatment of coronary artery disease patients. <i>Clinical Practice (London, England)</i> , 2012 , 9, 373-390	3	
12	Caution in interpreting the findings from small observational studies. <i>International Journal of Cardiology</i> , 2012 , 160, 71	3.2	
11	Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y ₁₂ receptor inhibitors. <i>Expert Review of Cardiovascular Therapy</i> , 2012 , 10, 1011-22	2.5	
10	Resistance to Antiplatelet Therapy 2011 , 1		
9	Role of ticagrelor in the treatment of coronary artery disease. <i>Clinical Investigation</i> , 2011 , 1, 429-437		
8	Diagnostics for aspirin resistance. <i>Molecular Diagnosis and Therapy</i> , 2008 , 12, 55-6	4.5	
7	Thienopyridine Response Variability and Resistance 77-93		

6	In search for an optimal antithrombotic regimen in patients with atrial fibrillation undergoing stenting. <i>Kardiologia Polska</i> , 2019 , 77, 817-819	0.9
5	Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y antagonists. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 272-280	5.1
4	To stop or continue aspirin before aortocoronary bypass operations-do we have enough evidence to adequately guide us?. <i>Journal of Thoracic Disease</i> , 2016 , 8, E578-80	2.6
3	CardioPulse: Platelet inhibitors and their differences. <i>European Heart Journal</i> , 2016 , 37, 323-6	9.5
2	The potential of genotype-guided antiplatelet therapy: promises and challenges. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018 , 3, 371-377	1.6
1	Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens.. <i>Journal of Thrombosis and Thrombolysis</i> , 2022 , 1	5.1